Sanofi invests $150M in Maze Therapeutics for Pompe disease treatment.
Originally Published 2 years ago — by Endpoints News
Sanofi will pay $150 million upfront and future equity to acquire Maze Therapeutics' Pompe disease program, with the potential for an additional $600 million in biobucks. Astellas Pharma will acquire Iveric Bio for $5.9 billion in cash, while Acelyrin plans to raise $370 million in one of the biggest biotech IPOs in recent years. Ovid Therapeutics is partnering with Graviton Bioscience to develop multiple second-generation ROCK2 inhibitors, and Initial Therapeutics has launched with $75 million to develop protein-based drugs. Meanwhile, AbbVie has discontinued its mid-stage cystic fibrosis program, and an FDA advisory committee has voted against AstraZeneca and Merck's bid to expand the label for Lynparza.